NEWS
Our Latest News
ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders
ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders
Private equity healthcare specialist ARCHIMED announces the sale of DIESSE to private equity firm Fremman Capital. The transaction caps a five-year partnership with DIESSE and marks the latter’s transformation into a leading clinical diagnostics innovator. The deal returns 4.6 times invested capital to shareholders.
ARCHIMED creates a leading specialized dermatological-focused CRO via the simultaneous purchase & merger of Symbio and Proinnovera
November
17,
2023
ARCHIMED top-ranked buyout fund MED I earns 4.5x on the sale of Vita
October
27,
2023
ARCHIMED Publishes White Paper – “Navigating the FHIR Landscape: A Strategic Approach for Healthcare IT Businesses”
September
27,
2023
368